Andrew Hill and Saye Khoo, Department of Pharmacology and Therapeutics, Liverpool University, UK Bryony Simmons, Imperial College, London, UK Nathan Ford, University of Cape Town, South Africa
64th Annual Meeting of AASLD, Washington DC, United States of America, November 2013 [Poster 1097]
TREATMENT COVERAGE IS LOW EVEN IN DEVELOPED COUNTRIES
Despite the long-term morbidity & mortality associated with untreated hepatitis C, data suggests that relatively few patient are being treated.
In Europe only 3.5% of infected individuals received antiviral
treatment by the end of 2010
(ranging from 16% in France to <1% in Poland)
In the USA only 21% of infected individuals had received
treatment by the end of 2007
Reasons for under-treatment:
- Under-diagnosis (80% of HCV cases are asymptomatic)
- Limitations of currently available medication
- The very high prices of drug treatment
Click on images to enlarge them
Also See: Will The New Hepatitis C Drugs Trigger A Battle Over Cost?
No comments:
Post a Comment